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Background: In recent decades, several studies have assessed the value of cardiac rehabilitation as secondary
prevention and have reported substantial reductions in readmissions. However, conclusive evidence is scarce. The
present study aims to evaluate the efficacy of a supervised exercise training program for improving percentages of
hospital readmission for cardiac causes in patients with myocardial ischemia in the first year after a cardiac event.
The effect on all-cause readmission, all-cause mortality, functional capacity, quality of life and adherence to regular
exercise is also discussed.
Methods/Design: This study will be conducted as a randomized controlled trial. Eligible patients will be randomly
assigned to a control group receiving standard care or to an intervention group which, in addition to standard care,
will take part in a supervised exercise training program consisting of three hours a week (spread over three
alternate days) of supervised exercise training for 10 weeks. Both groups will perform an exercise stress test and a
blood test during the first and third month after hospital discharge. The follow-up period will be 12 months after
hospital discharge. The primary outcome measures will be the percentage of patients readmitted, total number of
readmissions and length of hospitalization for cardiac disease during the first year after hospital discharge, and time
to first hospital admission for cardiac disease.
Discussion: A representative group of hospitalized patients after myocardial ischemia will be studied in order to
provide comprehensive data on the potential impact of a supervised exercise training program on hospital
readmission rates.
Trial registration: Current Controlled Trials ISRCTN57634424.
Keywords: Myocardial ischemia, Exercise therapy, Patient readmissionBackground
Cardiovascular disease (CVD) is a first-order public
health problem all over the world. In 2005, 17.5 million
CVD-associated deaths were recorded, and the World
Health Statistics 2008 report [1] predicts that this figure
will rise to 23.4 million by 2030. In Europe, CVD is the* Correspondence: nsantaul@althaia.cat
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health care costs. In Spain, CVD accounts for 35% of all
deaths and also has a high morbidity. It is particularly
important as a cause of death from age 65 onwards.
Improved diagnosis and more successful treatment of
acute illness have increased survival rates after myocar-
dial ischemia (MI). However this also means that the
prevalence of CVD is increasing.
In 1964, the World Health Organization (WHO) [2]
defined cardiac rehabilitation as "the sum of activity re-
quired to ensure cardiac patients the best possibletral Ltd. This is an Open Access article distributed under the terms of the
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by their own efforts, regain as normal as possible a place
in the community and lead an active life." Since then,
several institutions have introduced cardiac rehabilita-
tion in order to offer an integrated physical, psychological
and social approach to the treatment of the cardiac patient.
In cooperation with the American Association of Cardio-
vascular and Pulmonary Rehabilitation (AACVPR), the
American Heart Association (AHA) published recommen-
dations for cardiac rehabilitation programs (CRP) [3], speci-
fying that these programs should include physical training,
aggressive treatment of cardiovascular risk factors, dietary
guidance, psychosocial, occupational and physical activity,
and the use of all cardioprotective drugs with proven
efficacy in secondary prevention. In addition to these rec-
ommendations, and where possible, CRPs should include
appropriate secondary prevention measures as part of a
comprehensive multifactorial approach and should apply
the standards of European societies [4]. Secondary preven-
tion through exercise-based cardiac rehabilitation is the ap-
proach that has been most successful in reducing morbidity
and mortality in coronary artery disease, particularly after
MI; CRPs are recommended (Class I), by the European So-
ciety of Cardiology, the American Heart Association and
the American College of Cardiology [5]. Secondary preven-
tion and cardiac rehabilitation form a single strategy for
CRPs designed to reduce heart disease-related morbidity
and mortality and the disability it causes by 20-30% [6].
Despite the acknowledged benefits, however, CRPs are
currently underused. According to the European Cardiac
Rehabilitation Inventory Survey (2008)[7,8], of the 47.5%
of the countries that answered the survey, 42.10%
(including Belgium, Spain, and Italy) admitted ≤ 30% of eli-
gible patients for phase II of CRP; 15.79% (Luxembourg,
Sweden, UK) admitted >30-50% of eligible patients, and
15.79% (Germany, Iceland, Lithuania) admitted >50%.
Data were unavailable for the remaining 26%.
Studies on post-MI survival, readmissions and physical
rehabilitation date back to 1972 [9]. Most studies have
found no significant differences in readmissions post-
CRP but in 2005 one study concluded that global commu-
nity CRP significantly reduced cardiac readmission rates
[10]. In 2011, Heran et al. [11] published an updated sys-
tematic review of Jolliffe et al’s 2001 study, finding that
exercise-based CRPs significantly reduced hospital admis-
sions in the short term (<12 months), and in the same
year Lawler [12] published the first meta-analysis showing
a statistically significant reduction in MI recurrence with
an exercise-based CRP post-MI (OR 0.53; 95% CI: 0.38 -
0.76). Moreover, the few studies of the issue do not focus
on identifying the best exercise regimen for reducing
readmissions, but on whether the intervention itself af-
fects readmission rates. Only two of the studies presented
statistically significant decreases in readmissions [10,12].The value of readmission as an indicator of effectiveness
of exercise lies in the fact that it is an indirect measure of
clinical stability, so there is a clear need to study the rela-
tion between CRPs and readmission in MI patients.
The aim of this study is to evaluate the efficacy of a
supervised exercise training program for reducing car-
diac readmissions in patients with MI in the first year
after hospital discharge. This study will also provide a
detailed evaluation of the program’s effects on total mor-
tality, functional capacity, quality of life and adherence
to regular exercise. Our primary hypothesis is that a su-
pervised exercise training program will significantly re-
duce the incidence of cardiac readmissions in patients
with MI in the first year after hospital discharge. The
secondary hypothesis is that patients in the intervention
group will present significantly better functional cap-
acity, better quality of life, and lower mortality rate.
Methods/design
Study design
Open, controlled, randomized, hospital-based clinical
trial of patients admitted to the Cardiology Department
for MI.
Study subjects and recruitment
The study will recruit adult patients discharged from
hospital with MI as a primary diagnosis. Inpatients will
be actively identified by the cardiac nurse and the CRP
physiotherapist using daily bed lists.
The inclusion criteria will be: age over 18, diagnosis of
MI (myocardial ischemia, pre-infarct angina, cardiac an-
gina, other specific forms of chronic ischemic heart dis-
ease or unspecified ischemic heart disease) in the current
admission, residence in the catchment area of our hospital,
absence of cognitive deficit (Pfeiffer test: 0–2 mistakes),
sufficient autonomy to follow the cardiac rehabilitation
program (Barthel index >60), and willingness to partici-
pate in the study. Signed informed consent will be
obtained in all cases. Patients will be excluded if they have
symptoms of right heart failure producing pulmonary
hypertension or dyspnea caused by severe pulmonary
pathology, additional comorbidities affecting the prognosis
of cardiac disease, major comorbidities or limitations that
could interfere with exercise training program, cognitive
impairment or if they do not provide informed consent.
Randomization
Patients will be randomly assigned to one of two groups:
control or intervention. Patients in the intervention group
will be included in the supervised exercise training
program, while controls will receive standard care. A
randomization list will be produced by a computer-
generated random-number sequence in blocks of 10 to
ensure consistent patient distribution in both groups. The
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search Unit, which will also control allocation to each
group. The researchers will not be aware of the ran-
domization scheme.
Patients will be recruited by the cardiac nurse and the
CRP physiotherapist. Neither of them will know the
group assignment until the patient has signed the in-
formed consent form. The cardiac nurse or the physio-
therapist will then give the name and the patient
identification number to the Clinical Research Unit by
telephone. After this, participants in both groups will be
scheduled for their first visit with the cardiac nurse and
for the exercise stress test.
Study arms
Control
Patients assigned to the control group will receive the
standard care given at our hospital. During hospitalization,
the cardiac nurse or the physiotherapist will assess the car-
diovascular risk factors and other clinical variables in each
patient. This assessment will check diet, tobacco con-
sumption, hypertension, diabetes, exercise practice, family
heart disease, dyspnea, depressive symptoms and activities
of daily living. Patients will receive verbal and written in-
formation on cardiovascular risk factors from the cardiac
nurse or the physiotherapist. This educational information
will be related to cardiac disease, cardiovascular risk fac-
tors (hypertension, diabetes, cholesterol, triglycerides,
tobacco and other drugs, alcohol, stress, overweight, sed-
entary lifestyle), lifestyle (progressive rehabilitation activ-
ities, return to work, driving), diet, physical exercise
(phases of readaptation, phases of normal activity, work
activity, sexual activity), specific medication in case of car-
diac angina (nitroglycerin), pharmacological regimen,
complementary assessment (electrocardiogram, echocar-
diogram, chest X-ray, SPECT, cardiac catheterization, ar-
teriography, electrophysiological study) and treatment of
coronary artery disease (pharmacological, coronary angio-
plasty, surgical treatment). Hospitalized patients will be
instructed to do exercises to regain mobility in order to
maintain and improve muscular tone and peripheral circu-
lation, and will be taught breathing exercises by the
physiotherapist to improve their breathing patterns. Before
discharge, the physiotherapist will instruct patients on
how to return to physical activity.
Intervention
In addition to the usual hospital care, patients randomized
to the intervention group will be provided with a super-
vised outpatient exercise training program, according to
the results of the exercise stress test performed one month
after hospital discharge and bearing in mind the physical
limitations imposed by co-morbid conditions. The pro-
gram will be performed in the hospital and it will startwithin the three days after the exercise stress test. It will
comprise three hours a week (spread over three alternate
days) of supervised exercise training for 10 weeks. The
intervention will end after 10 weeks, regardless of whether
the patients have completed 30 sessions. Exercise classes
will be supervised by a physiotherapist and will consist of
10 minutes of warm-up and muscle stretching, 30 minutes
of aerobic exercises (cycloergometer), 15 minutes of iso-
tonic exercises for the upper and lower extremities and
5 minutes of cool-down. Moreover, instructions will be
given on self-pulse counting, subjective perception of ef-
fort using the Borg scale, relaxation exercises, breathing
techniques, postural health and minimizing physical effort.
Aerobic exercise intensity will be between 75-90% of the
maximum heart rate obtained in the previous exercise
stress test and progressing according to the rating of
perceived exertion (RPE: Borg scale 11–15). Resistance
training will be performed with 10–15 repetitions for
three sets, maintaining an RPE of 11–14. The physio-
therapist will check that patients are exercising at their
prescribed intensity with a pulse oximeter (Quirumed®
Health & Care).
After hospital discharge, patients in both groups will
have scheduled follow-up visits with a cardiac nurse at
the first month, and then after 3, 6 and 12 months (visits
1, 2, 3 and 4 respectively) since hospital discharge in
order to control the risk factors, reinforce education for
disease control and review adherence to cardiac medica-
tion and CRP follow-up.
Control patients will be asked to complete the same out-
come measures as the intervention group (See Figure 1).
Data collection and measures
Procedure
Each day, the cardiac nurse and the physiotherapist will
check the bed list of patients admitted to the Cardiology
Department. They will select the eligible patients after
assessing the clinical history and consulting the cardiolo-
gist. In the inpatient setting, the cardiac nurse or the
physiotherapist will give verbal and written information
related to the study to eligible patients and will resolve all
the patients’ doubts. These professionals will stress to the
patient that the randomization process will decide the
group inclusion. Before discharge (visit −1), eligible pa-
tients who agree to participate will be asked to give signed
informed consent. In this visit, the cardiac nurse will rec-
ord the following variables: education level, marital status,
living situation, employment status and comorbidities
(Charlson Comorbidity Index). On discharge (visit 0) the
cardiac nurse or the physiotherapist will contact the Clin-
ical Research Unit regarding the randomization process.
Once the cardiac nurse or the physiotherapist knows the
randomization group, they schedule the patient for the




Recruit participants as myocardial 
ischemia inpatients; obtain consent
Control group Intervention group
Visit 1 (Outcomes assessment 1 month)
Control blood test
Exercise stress test
Visit 4 (Outcomes assessment at 12 months)
Control blood test
Visit 3 (Outcomes assessment at 6 months)






(10 weeks, 3 alternate sessions/week, 1h/ session) 
Supervised outpatient exercise training program
Session:10 minutes of warm-up and muscle  
stretching + 30 minutes of aerobic exercises 
(cycloergometer) at 75-90% heart rate max 
(RPE:11-15)+ 15 minutes of isotonic exercises of 
upper and lower extremities (10-15 repetitions for 
three sets) (RPE :11-14) + 5 minutes of cool-down.
Figure 1 Study design flow-chart.
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3 and 4). During these visits, the cardiac nurse will de-
scribe ways of improving cardiovascular risk factors and
cardiac medication adherence, and will answer the pa-
tients’ questions. The following variables will be recorded:
attendance, systolic blood pressure (SBP), diastolic blood
pressure (DBP), heart rate, Body Mass Index (BMI), ab-
dominal circumference, Mediterranean diet, depressive
symptoms (Yesavage Geriatric Depression Scale), basic ac-
tivities of daily living (Barthel index), tobacco dependence
(Fargeström test), compliance with cardiac medication
(Haynes-Sackett test), taking sublingual nitroglycerin, hos-
pital emergency visits, hospital readmissions and mortal-
ity. Quality of life (EuroQol5) will be recorded at all visits
except visit 3. To address a possible cross-over effect, allpatients will be asked to complete a physical activity ques-
tionnaire (Capersen and Powell classification) at baseline
and in each follow-up visit. This test categorizes physical
activity in four levels: sedentary, irregular activity, non-
intensive regular activity, and intensive regular activity.
Further, during visit 1, the cardiac nurse will also rec-
ord the diagnostic reason for referral (MI: location, se-
verity, number of stents, ejection fraction), medication
prescribed and level of risk for cardiac rehabilitation. At
visit 4, the cardiac nurse will assess whether the patient
can return to work. Patients will be administered a satis-
faction survey with questions selected from the local
public health department’s satisfaction questionnaire.
Blood tests will be performed at visits 1, 2 and 4. The
following parameters will be determined: hemoglobin,
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sium, cholesterol, high density lipoprotein cholesterol,
low density lipoprotein cholesterol, triglycerides, creatine
kinase-MB (CK-MB), C-reactive protein, glycosylated
hemoglobin A1c (HbA1c), N-terminal Pro-B-type natri-
uretic peptide (NTproBNP), microalbumin and calcidiol.
The patient will do the exercise stress test at visit 1
and 2, under the guidance of the cardiologist and the
nurse. The Bruce protocol stress test will be used. Before
starting, the staff will describe the test to the patient and
give some recommendations such as taking a light meal
three hours before the test, avoiding stimulating drinks,
taking prescribed medication and wearing comfortable
shoes and clothes. In this protocol, exercise is performed
on a treadmill (QUINTON® Q-STRESS TM 55). The
leads of the ECG are placed on the chest wall. The
treadmill is started at 2.74 km/hr (1.7 mph) and at a gra-
dient (or incline) of 10%. At three minute intervals the
incline of the treadmill increases by 2%, and the speed
increases progressively. The exercise stress test will be
limited by clinical signs such as arrhythmias and/or ECG
changes and clinical symptoms such as general exhaus-
tion, claudication of the legs, chest pain or dyspnea [13].
The following exercise stress variables will be recorded:
theoretical maximum heart rate, real maximum heart rate,
baseline heart rate, chronotropic index, the level reached
on the exercise stress test, and time to recover initial heart
rate (1 and 3 minutes). The cardiac nurse will collect
blood before and after the exercise stress test in order to
determine the level of troponin I.
Additional information will be recorded in the inter-
vention group. Between visits 1 and 2, intervention pa-
tients will attend the training sessions. All sessions will
be supervised by the physiotherapist. In each session the
following values will be compiled: heart rate (initial,
maximum, final), oxygen saturation (initial, during ses-
sion, final), SBP (start, during session, final), DBP (initial,
during session, final), degree of dyspnea (initial, final)
and the level on the Borg scale. For each patient, the
physiotherapist will compile the data from the exercise
sessions and the number of physical sessions attended.
The cardiac nurse or physiotherapist will record the
cause of withdrawal during the follow-up. The cardiac
nurse will collect all data and enter them in a database
designed for this study.




The primary outcome measures will be the percentage
of patients readmitted, total number of readmissions and
length of hospitalization for cardiac disease during the
first year after hospital discharge and time to firsthospital readmission for cardiac disease. The primary
outcome will be assessed by an expert committee blind
to the patient’s treatment group.
Secondary outcome measures
Secondary outcomes are the following: percentage of pa-
tients readmitted, total number of readmissions and
length of hospitalization for all causes during the first
year after hospital discharge, all-cause death, all-cause
hospital emergency visits, functional capacity (exercise
stress test), quality of life (EuroQol5), adherence to CRP
(attendance at follow-up visits), adherence to cardiac
pharmacological treatment (Haynes-Sackett test), satis-
faction with assistance received (questions selected from
the local public health department’s questionnaire, Am-
bulatory Specialized Care 2008 [14]).
Demographic and clinical measures
Group allocation, sex, age, education level, marital status,
living situation, employment status, main diagnosis, diag-
nostic reason for referral, location, degree of involvement,
number of stents, the ejection fraction, comorbidities
(Charlson Comorbidity Index), maximum theoretical heart
rate, real maximum heart rate, baseline heart rate,
chronotropic index, the level reached on the exercise stress
test, time to recover initial heart rate (1 and 3 minutes)),
level of risk for cardiac rehabilitation, blood tests, cardiac
markers (NTproBNP, troponin I), SBP, DBP, BMI, abdom-
inal circumference, Mediterranean diet, depressive symp-
toms (Yesavage Depression Scale), basic activities of daily
living (Barthel Index), tobacco consumption (Fargeström
test), compliance with cardiac medication (Haynes-Sackett
method), taking sublingual nitroglycerin, physical activity
(Caspersen and Powell classification) and return to work.
Statistical issues
Sample size
To ensure a statistical power of 80% in order to detect
differences in the contrast of the null hypothesis (H0:
equal percentages of cardiac readmissions in the two
groups) through a two-tailed chi-square test for two in-
dependent samples, with a level of significance of 0.05,
and assuming that the percentage of cardiac readmissions
in the control group is 25% and the percentage in the
intervention group is 12%, each group will require 139 pa-
tients. Assuming a 5% loss to follow-up, we estimate that
146 patients will be needed in each arm.
Data collection and management
We will collect information on outcome at each stage of
recruitment, randomization, treatment allocation, follow-
up, and analysis in order to report patient flow according
to CONSORT guidelines [15]. We will record the number
of patients who meet exclusion criteria, the number of
Table 1 Summary of measures and variables according to the timeline
VISIT −1 0 1 2 3 4
Time (months) −1 0 1 3 6 12
Inclusion/exclusion criteria and informed consent X
Sociodemographic data (sex, age, education level, marital status, living situation,
employment status) and comorbidity (Charlson Index))
X
Cardiovascular risk factors (diet, alcohol, tobacco dependence - Fargeström test -
hypertension, diabetes, exercise practice, family heart disease), dyspnea, depressive
symptoms (Yesavage Depression Scale) and activities of daily living (Bartel Index)
X X X X X
Random allocation X
Diagnostic reason for referral (localization, severity, number of stents, ejection fraction) X
Medication prescribed X
Exercise stress test (theoretical maximum heart rate, real maximum heart rate, baseline
heart rate, chronotropic index, level reached, recovery time of the initial heart rate - 1 and
3 minutes-)
X X
Level of risk for cardiac rehabilitation X
Control blood test X X X
Anthropometric measures (Body Mass Index, abdominal circumference) X X X X
Systolic and diastolic blood pressure and baseline heart rate X X X X
Physical activity (Capersen and Powell classification) X X X X
Quality of life (EuroQol5) X X X
Cardiac medication adherence (Haynes-Sackett method) and taking sublingual
nitroglycerin
X X X X
Adherence to Cardiac Rehabilitation Program X X X X
Hospital emergencies visits, number of readmissions and total days of hospitalization X X X X
Mortality X X X X
Cause of withdrawal X X X X
Return to work X
Satisfaction with Cardiac Rehabilitation Program (satisfaction questionnaire of the local
public health department)
X
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ing to participate, the number of patients assigned to the
intervention arm, the number of patients assigned to the
control arm, the number of intervention visits, the num-
ber of patients who provided follow-up data, the number
of patients included in the analysis, and the number of
withdrawals.
To ensure that clinical data collection forms are accur-
ately entered into databases, we will periodically validate
the information collected in the database (detection of
missing and out-of-range values). To maintain the confi-
dentiality of the information, all patients will be identi-
fied by study numbers.
Statistical analysis
Continuous variables will be summarized using means
and standard deviations for normal distributions, and by
medians and the 25th and 75th percentiles for non-
normal distributions. Categorical variables will be sum-
marized using absolute values and relative frequency.
We will test for significant differences among the baselinecharacteristics of the control and intervention groups. For
continuous variables, we will use the Student's t-test if
both sample groups have normal distribution or the
Mann–Whitney U test otherwise. We will use the χ2 test
to compare categorical variables (or Fisher’s exact test in
2×2 contingency tables where the expected frequencies
are lower than 5).
Percentage of patients readmitted for cardiac disease
will be analysed through a two-tailed χ2 test for two in-
dependent samples, and time to first hospital readmission
for cardiac disease will be analysed as time to event with
Kaplan-Meier estimation and Cox proportional regression
models. The deaths occurring without hospitalization will
be introduced in the survival analysis as censored data.
Event or censored times for all patients will be measured
from the time of randomization (visit 0). All information
available on the primary and secondary end points will be
collected until the time of final contact with the patient,
including patients lost to follow-up, at which point follow-
up will be censored. Survival data will be presented graph-
ically using the Kaplan-Meier method. We will use the
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the effect size, we will report the unadjusted hazard ratios
(HR) and associated 95% confidence intervals (95% CI)
obtained in the bivariate Cox proportional regression
models.
To establish whether the allocation group is an inde-
pendent prognostic factor for cardiac readmission, we
will adjust for potential confounders in a multivariate
analysis. The model will be adjusted with the significant
covariates in bivariate analysis or those that were clinic-
ally significant. To estimate the effect size, we will report
the adjusted hazard ratios (HR) and associated 95% con-
fidence intervals (95% CI) obtained in the multivariate
Cox proportional regression models.
Outcomes will be analysed on an intention-to-treat
basis. A two-sided α-level of 0.05 will be considered sta-
tistically significant. Data will be analysed using IBM
SPSS Statistics for Windows v.20 and Stata v.10.
Ethical approval
The protocol has been approved by the independent
Ethical Committee of Clinical Research of our hospital.
Before recruitment, all patients will provide written, in-
formed consent to participate. The study will comply
with all local legal and regulatory requirements and with
the Declaration of Helsinki. Trial registration on Current
Controlled Trials is ISRCTN57634424 a date 30/04/
2010.
Limitations
One limitation of this study is its open design, since it
will not be possible to blind the intervention and both
patients and staff will know to which group they have
been assigned. This may affect the degree of response,
especially in the control group. Another limitation may
be the difficulty of including patients due to the large
size of the catchment area and its mainly rural nature.
This may restrict the inclusion process due to the dis-
tance and transport problems, and may limit the exter-
nal validity.
Discussion
The objectives pursued by this project have a direct im-
pact on the welfare of patients with myocardial ischemia.
Reducing cardiac readmissions and improving quality of
life and functional status of the patient accelerate return
to normal life and shorten convalescence time. In
addition, during admission and follow-up, the patient
and family will receive detailed information on lifestyle
habits, physical exercise and aspects to consider in order
to favour active control of the disease by the patient and
to increase safety, both highly important factors for re-
ducing the number of readmissions.From the standpoint of health planning and manage-
ment, the findings of the study may entail substantial
savings in the budgets of health services in the country,
reducing readmissions and the total length of hos-
pitalization in a disease as frequent as myocardial ische-
mia. Thus, this clinical trial may encourage the systematic
implementation of supervised exercise training program
on cardiac rehabilitation programs in our environment.
The intervention will not be overly complex and can be
performed easily by well-trained health professionals, and
could be widely applied if it demonstrates a clinically rele-
vant degree of efficacy. In the reference area of our hos-
pital, there is no central unit that organizes secondary
prevention and supervised exercise training programs for
cardiac patients. As a result, our patients are not currently
undergoing treatment at other centers.
This multidisciplinary experimental clinical study will
promote research in groups of MI patients who are rep-
resentative of usual clinical practice. It includes validated
health-related quality of life outcome measures and hos-
pital admission.
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